Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical study

The quality, pharmacokinetic and pharmacodynamic profiles, safety and immunogenicity must be compared to demonstrate the bio-similarities of recombinant human insulin and insulin analogues. To confirm these bio-similarities in clinical studies, it is necessary to adhere to a multi-phased approach, s...

Full description

Saved in:
Bibliographic Details
Main Authors: Irina A. Proskurina, Alexander Y. Mayorov, Dmitriy V. Gorachev, Natalya D. Bunyatyan
Format: Article
Language:English
Published: Endocrinology Research Centre 2016-07-01
Series:Сахарный диабет
Subjects:
Online Access:https://www.dia-endojournals.ru/jour/article/view/7793
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850141140501659648
author Irina A. Proskurina
Alexander Y. Mayorov
Dmitriy V. Gorachev
Natalya D. Bunyatyan
author_facet Irina A. Proskurina
Alexander Y. Mayorov
Dmitriy V. Gorachev
Natalya D. Bunyatyan
author_sort Irina A. Proskurina
collection DOAJ
description The quality, pharmacokinetic and pharmacodynamic profiles, safety and immunogenicity must be compared to demonstrate the bio-similarities of recombinant human insulin and insulin analogues. To confirm these bio-similarities in clinical studies, it is necessary to adhere to a multi-phased approach, starting with the pharmacokinetics and pharmacodynamics of the study drugs. In this article, in accordance with modern approaches to drug research, evaluation of the pharmacokinetics and pharmacodynamics of recombinant human insulin and analogues of human insulin (biosimilar drugs) is performed in a double-blind, randomised crossover euglycaemic hyperinsulinaemic clamp study.This article describes the main approaches to the evaluation of the pharmacokinetic and pharmacodynamic parameters of recombinant human insulin preparations and insulin analogues during a euglycaemic hyperinsulinaemic clamp study. The inclusion criteria for the sample selection, design and conditions of the study, methods for the suppression of endogenous insulin, recommendations for doses of drugs, duration of the study and choice of primary and secondary pharmacokinetic and pharmacodynamic parameters for bio-similar insulin products (which depend on the duration of their effects) are described.
format Article
id doaj-art-c78b0f616f6e43df9840cb2fd1e823af
institution OA Journals
issn 2072-0351
2072-0378
language English
publishDate 2016-07-01
publisher Endocrinology Research Centre
record_format Article
series Сахарный диабет
spelling doaj-art-c78b0f616f6e43df9840cb2fd1e823af2025-08-20T02:29:34ZengEndocrinology Research CentreСахарный диабет2072-03512072-03782016-07-0119325125910.14341/DM2003446-497417Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical studyIrina A. Proskurina0Alexander Y. Mayorov1Dmitriy V. Gorachev2Natalya D. Bunyatyan3Scientific Сenter for Expert Evaluation of Medical ProductsEndocrinology Research Centre; I.M.Sechenov First Moscow State Medical UniversityScientific Сenter for Expert Evaluation of Medical ProductsScientific Сenter for Expert Evaluation of Medical ProductsThe quality, pharmacokinetic and pharmacodynamic profiles, safety and immunogenicity must be compared to demonstrate the bio-similarities of recombinant human insulin and insulin analogues. To confirm these bio-similarities in clinical studies, it is necessary to adhere to a multi-phased approach, starting with the pharmacokinetics and pharmacodynamics of the study drugs. In this article, in accordance with modern approaches to drug research, evaluation of the pharmacokinetics and pharmacodynamics of recombinant human insulin and analogues of human insulin (biosimilar drugs) is performed in a double-blind, randomised crossover euglycaemic hyperinsulinaemic clamp study.This article describes the main approaches to the evaluation of the pharmacokinetic and pharmacodynamic parameters of recombinant human insulin preparations and insulin analogues during a euglycaemic hyperinsulinaemic clamp study. The inclusion criteria for the sample selection, design and conditions of the study, methods for the suppression of endogenous insulin, recommendations for doses of drugs, duration of the study and choice of primary and secondary pharmacokinetic and pharmacodynamic parameters for bio-similar insulin products (which depend on the duration of their effects) are described.https://www.dia-endojournals.ru/jour/article/view/7793biosimilarrecombinant human insulininsulin analogueseuglycaemic hyperinsulinaemic clamp-study
spellingShingle Irina A. Proskurina
Alexander Y. Mayorov
Dmitriy V. Gorachev
Natalya D. Bunyatyan
Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical study
Сахарный диабет
biosimilar
recombinant human insulin
insulin analogues
euglycaemic hyperinsulinaemic clamp-study
title Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical study
title_full Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical study
title_fullStr Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical study
title_full_unstemmed Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical study
title_short Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical study
title_sort modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in i phase clinical study
topic biosimilar
recombinant human insulin
insulin analogues
euglycaemic hyperinsulinaemic clamp-study
url https://www.dia-endojournals.ru/jour/article/view/7793
work_keys_str_mv AT irinaaproskurina modernapproachtotheevaluationofthepharmacokineticsandpharmacodynamicsofbiosimilarrecombinanthumaninsulinandinsulinanaloguesiniphaseclinicalstudy
AT alexanderymayorov modernapproachtotheevaluationofthepharmacokineticsandpharmacodynamicsofbiosimilarrecombinanthumaninsulinandinsulinanaloguesiniphaseclinicalstudy
AT dmitriyvgorachev modernapproachtotheevaluationofthepharmacokineticsandpharmacodynamicsofbiosimilarrecombinanthumaninsulinandinsulinanaloguesiniphaseclinicalstudy
AT natalyadbunyatyan modernapproachtotheevaluationofthepharmacokineticsandpharmacodynamicsofbiosimilarrecombinanthumaninsulinandinsulinanaloguesiniphaseclinicalstudy